NOVELTY - Esterification product (I) of nitrobenzoic acid is reduced and alkoxy carbonylated. The alkoxy carbonylated product (II) is nitrated and N-alkylated with 5-(4'-bromomethyl-biphenyl-2-yl)-1-trityl-1H-tetrazole to obtain an alkylated product (IV). Catalytic hydrogenation of the compound (IV) is carried out and the hydrogenation product is cyclized to obtain benzoimidazole-substituted compound (VI). The compound (VI) is condensed with carbonic acid 1-chloro-ethyl ester cyclohexyl ester. The obtained condensate is deprotected in solvent mixture to obtain candesartan cilexetil.    USE - Manufacture of candesartan cilexetil (claimed).    ADVANTAGE - The candesartan cilexetil of high purity is manufactured economically with high yield, reduced environmental pollution, and with improved productivity.    DETAILED DESCRIPTION - Nitrobenzoic acid is esterified to obtain esterification product of formula (I). The compound (I) is reduced and subjected to alkoxy carbonylation to obtain a carbonylated product of formula (II). The compound (II) is nitrated and N-alkylation of the nitrated product of formula (III) is carried out with 5-(4'-bromomethyl-biphenyl-2-yl)-1-trityl-1H-tetrazole to obtain an alkylated product of formula (IV). Catalytic hydrogenation of the compound (IV) is carried out to obtain amino-substituted compound of formula (V). The compound (V) is cyclized to obtain benzoimidazole-substituted compound of formula (VI). The compound (VI) is hydrolyzed under alkaline conditions to obtain 2-ethoxy-3-(2'-(1-trityl-1H-tetrazol-5-yl)-biphenyl-4-ylmethyl)-3H-benzoimidazole-4-carboxylic acid. The obtained acid compound is condensed with carbonic acid 1-chloro-ethyl ester cyclohexyl ester to obtain 2-ethoxy-3-(2'-(1-trityl-1H-tetrazol-5-yl)-biphenyl-4-ylmethyl)-3H-benzoimidazole-4-carboxylic acid 1-cyclohexyloxycarbonyloxy-ethyl ester. The obtained condensate is deprotected in mixture of toluene and methanol to obtain candesartan cilexetil.    R=1-6C alkyl.    INDEPENDENT CLAIMS are included for the following:    (1) intermediate of formula (IV);    (2) intermediate of formula (V); and    (3) use of the intermediates for manufacturing candesartan cilexetil.